Insmed’s COVID-19 Response
As we navigate the global COVID-19 pandemic, Insmed is taking steps to ensure the health and safety of the patients we serve as well as our own employees. We are also doing our part to support our local communities and aid in the global containment effort.
Here are a few updates on our business:
Investigator-Initiated Study
In April, Insmed announced that we are funding and providing clinical drug supply for the STOP-COVID19 (Superiority Trial of Protease inhibition in COVID-19) trial, an investigator-initiated study of brensocatib (formerly known as INS1007) in hospitalized patients with COVID-19. The mechanism of action of brensocatib, a candidate that we are advancing into Phase 3 development for patients with bronchiectasis, suggests that it may have broad applicability in a range of neutrophil-mediated diseases. This could include acute respiratory distress syndrome (ARDS), a severe outcome of COVID-19. Based on this rationale, we are pleased to support this investigator-initiated trial. In parallel, we continue to pursue an in vivo mouse model to better understand the potential of brensocatib in preventing ARDS.
Community Support
Since the start of the pandemic, Insmed has worked hand in hand with the biopharmaceutical industry to support evolving needs in our communities. Some of the ways we have lent support include donating personal protective equipment to those on the front lines and sharing iPads with local hospitals to enable critically ill patients to see their loved ones. We continue to look for ways we can be of service during this challenging time.
Supply Chain
Our supply chain is strong, with no disruptions to date in the production of our approved medicine or our pipeline candidates. We currently have enough active pharmaceutical ingredient of our approved medicine to meet anticipated global requirements through the end of 2022. Our third-party manufacturers continue to operate to ensure an uninterrupted supply of medication while taking all necessary precautions to protect their workers’ safety.
Patient Support
We know that patients living with refractory Mycobacterium avium complex (MAC) lung disease may feel especially concerned at this time. We encourage you to speak with your doctor for specific medical advice related to COVID-19. For patients in the U.S. taking our approved product, our patient services team remains available and can be reached at 1-833-ARIKARE (1-833-274-5273) to support enrolled patients. In addition, our Arikares Trainers can provide remote device training for new patients who initiate treatment with our approved product.
Our Employees
All Insmed employees are currently working remotely to aid in the global containment effort. This includes office-based and field-based employees in all geographies. We are deeply committed to ensuring that our employees have the support they need during this unprecedented time.
Healthcare Professionals (HCPs)
While we have taken our field-based employees out of the field to allow HCPs to focus on critical relief efforts, we remain dedicated to supporting their needs through remote, virtual interactions. HCPs who have specific questions should call 1-844-4-INSMED (1-844-446-7633) or email medicalinformation@insmed.com.
Insmed is working hand in hand with the entire biopharmaceutical industry to support evolving needs in the fight against COVID-19. We know this is a rapidly changing situation. We are closely monitoring the latest information so we can do everything in our power to protect the health of the patients we serve and the employees who enable us to do so.
For the most up-to-date guidance on COVID-19, visit trusted sources such as the World Health Organization (WHO) or the Centers for Disease Control and Prevention (CDC).
Contact Us
